ParcelBio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ParcelBio - overview
Established
2024
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2024, Parcel Biosciences Inc d. b. a. , ParcelBio provides RNA-based drugs.
The company was co-founded by David Weinberg (CEO), and Chris Carlson. In May 2026, ParcelBio raised USD 13 million in seed funding led by new investor Breyer Capital, with participation from other new investors General Catalyst Partners, Y Combinator, Metaplanet Holdings, ZAKA, and SurgePoint Capital. Other unspecified investors also participated in the round. The company offers programmable technology that delivers mRNA to various cell types throughout the body.
The firm Stabilized Targeted mRNA Platform (STAmP) offers a nanoparticle-free solution. It stabilizes mRNA and incorporates an interchangeable lock-and-key-like targeting mechanism, enabling fully customizable mRNA medicines tailored to specific therapeutic needs. The company will use the May 2026 funding to support platform development and advance its mRNA therapeutic pipeline.
Current Investors
Pioneer Fund, General Catalyst Partners, Y Combinator
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals
Website
www.parcelbio.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
ParcelBio - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.